Colonoscopy, endoscopy, fecal calprotectin, CRP, imaging, intestinal ultrasound, and monitoring research.
Page 23 of 33 · 1560 articles
People with IBD may have a higher-than-expected rate of biopsy-confirmed celiac disease in this Northern Indian cohort, and standard anti-tTG blood tests can be falsely positive in IBD. Confirmatory duodenal biopsy is...
People with IBD may face higher-than-expected rates of hypertensive disorders in pregnancy; identifying predictors could help target monitoring and preventive strategies. The study suggests prior HDP and gestational...
This study provides region-specific pediatric IBD data from the Philippines, highlighting prevalence of very-early-onset disease, perianal involvement in Crohn's, and factors (diagnostic delay, wasting, pancolitis)...
This study provides real-world data on how well ustekinumab is kept on treatment and its safety in an Arab IBD population—information that can help patients and clinicians understand longer-term use outside clinical...
Patients with Crohn's reported more relapses and are more likely to see diet as a relapse trigger; nutritional therapy (including elemental diets) is used more often in Crohn's than UC in this Japanese sample. This...
Faster remission can reduce symptoms, school disruption, and steroid exposure for children with IBD. If earlier infliximab level checks reliably speed remission, clinicians could adjust dosing sooner to improve outcomes.
S1P receptor modulators are an emerging oral class of advanced therapy for moderate-to-severe ulcerative colitis; a systematic review that pools multiple RCTs helps clarify how effective and safe the class appears to be...
The criteria were tested specifically in patients with psoriasis, uveitis, or IBD presenting with chronic back pain—groups at higher risk of axSpA—so results inform how well the new criteria perform in these real‑world...
Researchers aim to create computational tools to identify cell–cell signaling that controls the mix of epithelial cell types in mucosal tissues. For IBD, such tools could help reveal signals that change intestinal...
Frequent, accurate assessment of bowel inflammation and fibrosis is critical for Crohn's disease care. Ultrasound is safe, accessible, and could provide a low-cost biomarker to monitor disease activity, fibrosis, and...
Injection site pain and local reactions can affect comfort and willingness to continue injectable biologic therapy.
SpA is a frequent but underrecognized extraintestinal manifestation in people with IBD; validated screening tools can help identify patients who need rheumatology evaluation. Earlier detection may address joint symptoms...
Severe ulcerative colitis can be linked to rare cardiac rhythm disturbances; recognizing bradycardia during flares may prompt appropriate evaluation and monitoring. The case signals clinicians to consider cardiac causes...
The paper presents integrated preclinical evidence that a multi-herb formula (GQG) can reduce inflammation and alter gut microbiota and metabolites in a mouse model of ulcerative colitis, highlighting possible mechanisms...
Cure8 could only read part of this source from PubMed Central, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Research and clinical...
The study provides real-world effectiveness and safety data for risankizumab in a largely difficult-to-treat Crohn's population, showing about half achieved corticosteroid-free clinical remission at 24 weeks —...
The oral microbiome in children with Crohn's disease appears to reflect disease severity and changes with treatment, suggesting a potential noninvasive biomarker for monitoring response to nutritional therapies like CDED...
People with IBD or other autoimmune diseases are often concerned that vaccines might work less well for them.
Patients with IBD receiving biologic therapy need regular lab monitoring, TB screening, vaccinations, and bone-density assessment; many of these services were underused before the dashboard. Tools that improve those...
This study suggests that people with PSC-IBD may respond differently to some biologic treatments: infliximab and vedolizumab had similar early effectiveness versus IBD alone, but ustekinumab showed a lower early response...
People with IBD and their clinicians are often looking for objective ways to monitor disease-related changes. This study suggests morning HRV may add useful, noninvasive information about condition and readiness in an...
This large pediatric registry study suggests children starting infliximab biosimilars have similar 12‑month clinical outcomes and treatment durability as those starting the originator drug — reassuring for patients and...
Frailty is linked to worse outcomes in older people with IBD, so knowing how common it is—and which patients are at higher risk—can influence monitoring and treatment planning.
Shows which IBD comorbidities may be driven in part by shared inherited genetic risk and which likely reflect non-genetic factors, information that could shape future risk stratification and screening approaches for...
Granulomas on biopsy can indicate infection, IBD (including Crohn’s), sarcoidosis, or malignancy; knowing the likely causes and gaps in diagnostic testing helps guide follow-up. The diagnosis mix differed by organ and...
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...
Automating bowel wall thickness measurement could make intestinal ultrasound more consistent and reliable for monitoring inflammation in IBD, which matters to patients and clinicians tracking disease activity.
Patients with IBD who are frail appear to have a substantially higher risk of infections while on biologic therapies compared with fit patients. Recognizing frailty before and during treatment could improve risk...
People with IBD commonly have extraintestinal symptoms (mood disorders, fatigue, pain, nutritional problems) that affect quality of life and need proactive identification and management in primary care.
This trial could provide long-term safety data on guselkumab for children with moderate-to-severe Crohn's disease or ulcerative colitis and offers continued access to the drug for participants from earlier pediatric...
A Phase 3 trial is testing whether guselkumab can produce MRI-detected transmural healing in Crohn's disease — an outcome that could reflect deeper intestinal healing than symptom improvement alone. If successful, it may...
This Phase 3 trial directly compares two IL-23–targeting biologic therapies in moderate-to-severe Crohn's disease with a 52-week deep remission endpoint, which could inform future treatment choices if results are...
Long-term safety data on biologics and thiopurines are important for people with ulcerative colitis because they help patients and clinicians weigh risks (including malignancies and pregnancy-related outcomes) when...
A new IL-23–targeting therapy (JNJ-78934804) is being tested against an approved IL-23 inhibitor (guselkumab) in a large Phase 3 trial for moderate–severe ulcerative colitis, which could affect future treatment options...
This trial tests whether pomegranate juice can lower fecal calprotectin, a commonly used marker of intestinal inflammation, in people with IBD in remission. If effective, such a dietary approach could be of interest to...
A new Phase 3 trial is testing icotrokinra, an oral investigational drug, for induction and maintenance of remission in moderate–severe ulcerative colitis. Trials like this could expand treatment options if the drug...
An AI-derived score that combines inflammation severity and extent may better predict relapse risk in ulcerative colitis than severity alone. That could help identify patients in endoscopic remission who still face...
The study suggests why a JAK1 inhibitor (filgotinib) may work better in some gut regions than others, offering a possible explanation for mixed clinical trial results in Crohn's disease. This could influence how future...
Intestinal fibrosis is a serious complication of long-standing ulcerative colitis. Identifying NET-related biomarkers (IL1RN, MUC1, SERPINA1) could help researchers develop better diagnostic tools or treatments targeting...
An updated FDA drug label affects how ustekinumab is prescribed and monitored. It confirms Crohn’s disease and ulcerative colitis as approved uses and highlights safety concerns (infections, TB screening, malignancy)...
People with IBD and those on commonly used biologics may have different early T cell responses and faster waning after SARS-CoV-2 vaccination, which could affect timing or interpretation of immune monitoring and booster...
CDI occurs more often in hospitalized people with IBD than in those without IBD. Understanding which patients are at higher risk for death or complications can help hospitals prioritize early testing and management to...
Extraintestinal manifestations (EIMs) can significantly affect people with IBD and may require multidisciplinary care. Knowing how often EIMs are documented and which patients are more likely to have them helps...
PROM completion is important for monitoring symptoms and disease control between visits. The study shows a single empowerment campaign produced a short‑term boost in PROM response but not sustained engagement,...
Researchers found distinct microbial and host molecular features in the appendices of children with IBD, which could help explain local immune activation and guide future studies of disease mechanisms or biomarkers.
The study tests whether adding MRI-based transmural assessment to a fecal-calprotectin–guided (CALM) strategy improves the ability to keep people with Crohn’s disease in corticosteroid-free clinical remission and may...
The trial tests ustekinumab dosing, safety, and pharmacokinetics specifically in children with moderate–severe Crohn’s — information that can affect pediatric treatment options and dosing guidance once results are...
If sodium intake influences gut proteolytic activity, microbiota and inflammation, the findings could help tailor dietary guidance and personalized nutrition strategies for people with Crohn’s disease.
